{"id":228658,"date":"2017-07-18T17:00:04","date_gmt":"2017-07-18T21:00:04","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/stem-cell-therapy-for-heart-failure-gets-a-gold-standard-trial-scientific-american.php"},"modified":"2017-07-18T17:00:04","modified_gmt":"2017-07-18T21:00:04","slug":"stem-cell-therapy-for-heart-failure-gets-a-gold-standard-trial-scientific-american","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/stem-cell-therapy-for-heart-failure-gets-a-gold-standard-trial-scientific-american.php","title":{"rendered":"Stem Cell Therapy for Heart Failure Gets a Gold-Standard Trial &#8211; Scientific American"},"content":{"rendered":"<p><p>    In the days after a heart attack, surviving patients and their    loved ones can breathe a sigh of relief that the immediate    danger is overbut the scar tissue that forms during the long    healing process can inflict lasting damage. Too often it    restricts the heart's ability to fill properly between beats,    disrupting rhythm and ultimately leading to heart failure. Yet    a new possible treatment may help to revitalize an injured    ticker.  <\/p>\n<p>    A cadre of scientists and companies is now trying to prevent or    reverse cardiac damage by infusing a cocktail of stem cells    into weakened hearts. One company, Melbourne, Australiabased    Mesoblast, is already in late-stage clinical trials, treating    hundreds of chronic heart failure patients with stem cell    precursors drawn from healthy donors' hip bones. A randomized    trial that includes a placebo group is scheduled to complete    enrollment next year.  <\/p>\n<p>    Mesoblast's earlier-stage trials, published in 2015 in    Circulation Research, found that patients who received    injections of its cell mixture had no further problems related    to heart failure.  <\/p>\n<p>    Promising results from the new trial would be a major step    forward for a field that has long been criticized for studies    that are poorly designed, incomplete or lack control-group    comparisons, as well as for the peddling of unproved therapies    in many clinics worldwide.  <\/p>\n<p>    Another company, Belgium-based TiGenix, hopes to attack scar    tissue before it forms by treating patients with a mixture of    heart stem cells within seven days of a heart attack. This    approach has just completed phase II trials, but no findings    have yet been published.  <\/p>\n<p>    There are still many unanswered questions about how stem    cellstypically derived from bonescould help heal the heart.    Leading theories suggest they may help fight inflammation,    revitalize existing heart cells, or drive those cells to divide    or promote new blood-vessel growth, says Richard Lee, leader of    the cardiovascular program at the Harvard Stem Cell Institute.    Other stem cell scientists, including Joshua Hare, who    conducted earlier-stage Mesoblast research and directs the    Interdisciplinary Stem Cell Institute at the University of    Miami, say the cells may work in multiple ways to heal scar    tissue. According to Hare, the stem cells could ultimately be a    truly regenerative treatment.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See the article here:<\/p>\n<p><a target=\"_blank\" href=\"https:\/\/www.scientificamerican.com\/article\/stem-cell-therapy-for-heart-failure-gets-a-gold-standard-trial\/\" title=\"Stem Cell Therapy for Heart Failure Gets a Gold-Standard Trial - Scientific American\">Stem Cell Therapy for Heart Failure Gets a Gold-Standard Trial - Scientific American<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> In the days after a heart attack, surviving patients and their loved ones can breathe a sigh of relief that the immediate danger is overbut the scar tissue that forms during the long healing process can inflict lasting damage.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/stem-cell-therapy\/stem-cell-therapy-for-heart-failure-gets-a-gold-standard-trial-scientific-american.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[25],"tags":[],"class_list":["post-228658","post","type-post","status-publish","format-standard","hentry","category-stem-cell-therapy"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/228658"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=228658"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/228658\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=228658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=228658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=228658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}